人附睾蛋白4和糖链抗原125在上皮性卵巢肿瘤中表达及意义

Expressions and significances of HE4 and CA125 in epithelial ovarian cancer

目的探讨人附睾蛋白4(human epididymis protein 4,HE4)和糖链抗原125(carbohydrate antigen 125,CA125)在上皮性卵巢癌中的表达,及其对上皮性卵巢癌筛查和疗效判定的价值。方法上皮性卵巢癌患者50例为卵巢癌组,卵巢良性肿瘤患者51例为良性肿瘤组,体检健康女性100例为对照组,采用ELISA法检测3组血清HE4和CA125水平,比较3组HE4和CA125阳性率及卵巢癌组HE4和/或CA125阳性患者完全缓解率、肿瘤进展率和肿瘤复发率。结果卵巢癌组血清HE4[305.46(14.32,1 141.35)pmol/L]和CA125[243.99(4.50,1 073.25)u/mL]水平高于良性肿瘤组[63.51(13.96,296.43)pmol/L、45.56(0.03,71.23)u/mL]和对照组[39.64(25.57,59.15)pmol/L、18.42(4.40,23.92)u/mL],良性肿瘤组高于对照组(P<0.05);卵巢癌组HE4和CA125阳性率(94.0%、88.0%)明显高于良性肿瘤组(31.4%、37.3%)和对照组(2.0%、2.0%)(P<0.05),良性肿瘤组高于对照组(P<0.05);卵巢癌组HE4阳性患者完全缓解率(42.5%)、肿瘤进展率(47.5%)和肿瘤复发率(10.0%)与CA125阳性患者(45.9%、40.5%、13.5%)比较差异无统计学意义(P>0.05);HE4和CA125均阳性患者完全缓解率(14.3%)、肿瘤进展率(14.3%)低于HE4阳性者和CA125阳性者,肿瘤复发率(71.4%)高于HE4阳性者和CA125阳性者(P<0.05)。结论 HE4和CA125可用于筛查上皮性卵巢癌,二者联合检测可判定上皮性卵巢癌的预后。

Objective To explore the expressions of human epididymis protein 4(HE4)and carbohydrate antigen 125(CA125)in epithelial ovarian cancer(EOC)and the value to the screening of EOC and evaluation of therapeutic effect.Methods The serum HE4 and CA125 levels were detected by ELISA method in 50 patients with EOC(EOC group),51 patients with benign ovarian tumor(benign tumor group),and 100 health volunteers(control group).The positive rates of HE4 and CA125 were compared in three groups.The complete remission rates,tumor progression rates and tumor recurrence rates were compared among patients with positive HE4 and/or positive CA125 in EOC group.Results The serum HE4 and CA125 levels were significantly higher in EOC group(305.46(14.32,1 141.35)pmol/L,243.99(4.50,1 073.25)u/mL)than those in benign tumor group(63.51(13.96,296.43)pmol/L,45.56(0.03,71.23)u/mL)and control group(39.64(25.57,59.15)pmol/L,18.42(4.40,23.92)u/mL),and in benign tumor group than those in control group(P<0.05).The positive rates of HE4 and CA125 were significantly higher in EOC group(94.0%,88.0%)than those in benign tumor group(31.4%,37.3%)and control group(2.0%,2.0%)(P<0.05),and in benign tumor group than those in control group(P<0.05).There were no significant differences in the complete remission rates,tumor progression rates and tumor recurrence rates in patients with positive HE4(42.5%,47.5%,10.0%)and patients with positive CA125(45.9%,40.5%,13.5%)in EOC group(P>0.05).The complete remission rate and tumor progression rate in patients with both positive HE4 and CA125 were significantly lower and the tumor recurrence rate was significantly higher in EOC group(14.3%,14.3%,71.4%)than those in patients with positive HE4 or CA125(P<0.05).Conclusion HE4 and CA125 can be used to screen EOC,and the combined test can predict the prognosis of EOC.